User profiles for Maria Caterina Rotiroti
 | Maria Caterina RotirotiDana-Farber Cancer Institute Verified email at dfci.harvard.edu Cited by 1163 |
[HTML][HTML] CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
…, Z Ehlinger, W Reynolds, R Lynn, MC Rotiroti… - Nature medicine, 2021 - nature.com
Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric
antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with …
antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with …
Co-opting signalling molecules enables logic-gated control of CAR T cells
AM Tousley, MC Rotiroti, L Labanieh, LW Rysavy… - Nature, 2023 - nature.com
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …
[HTML][HTML] GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
…, J Mahdi, A Reschke, EH Nie, IJ Chau, MC Rotiroti… - Nature, 2022 - nature.com
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs)
are universally lethal paediatric tumours of the central nervous system 1 . We have …
are universally lethal paediatric tumours of the central nervous system 1 . We have …
[HTML][HTML] Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia
Chimeric antigen receptor (CAR)-redirected T lymphocytes are a promising immunotherapeutic
approach and object of pre-clinical evaluation for the treatment of acute myeloid …
approach and object of pre-clinical evaluation for the treatment of acute myeloid …
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-risk
neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
[HTML][HTML] CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through …
…, KA Murphy, A Manousopoulou, K Kohler, MC Rotiroti… - Blood, 2020 - Elsevier
CD19 CAR T cells have revolutionized the treatment of relapsed and refractory (R/R) large
B cell lymphomas (LBCL), mediating durable complete responses in approximately 40-50% …
B cell lymphomas (LBCL), mediating durable complete responses in approximately 40-50% …
[HTML][HTML] Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system
The successful implementation of chimeric antigen receptor (CAR)-T cell therapy in the
clinical context of B cell malignancies has paved the way for further development in the more …
clinical context of B cell malignancies has paved the way for further development in the more …
Lenalidomide enhances CD23. CAR T cell therapy in chronic lymphocytic leukemia
S Tettamanti, MC Rotiroti… - Leukemia & …, 2022 - Taylor & Francis
Chimeric antigen receptors (CAR)-modified T cells are an emerging therapeutic tool for
chronic lymphocytic leukemia (CLL). However, in patients with CLL, well-known T-cell defects …
chronic lymphocytic leukemia (CLL). However, in patients with CLL, well-known T-cell defects …
IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
Acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric
patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells …
patients. Adoptive cell therapy by chimeric antigen receptor (CAR)-engineered T cells …
[HTML][HTML] Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use
…, S Zaninelli, C Cuofano, I Cattaneo, MC Rotiroti… - Cytotherapy, 2022 - Elsevier
Our center performs experimental clinical studies with advanced therapy medicinal products
(ATMPs) based on polyclonal T cells, all of which are currently expanded in standard T-…
(ATMPs) based on polyclonal T cells, all of which are currently expanded in standard T-…